FTO and renal cell carcinoma: Overall, analysis of the genomic regions encoding m6A players disclosed no (FTO) or less than 1% (METTL3, METLL14, WTAP and ALKBH5) genomic alterations in RCC, except for VIRMA, which disclosed an amplification frequency of 1.4% (Figure 1A).